Hepatic VLDL Synthesis (VLDL Synthesis)

Hepatic VLDL (very-low-density lipoprotein) synthesis is the process by which liver cells (hepatocytes) assemble and secrete VLDL particles. These lipoproteins transport endogenous triglycerides, cholesterol, and other lipids from the liver to peripheral tissues. The process involves triglyceride mobilization, apolipoprotein B100 synthesis and lipidation (facilitated by MTP), particle maturation, and vesicular transport and secretion. It is regulated by factors such as insulin and caloric intake. Dysregulation of this pathway is implicated in hypertriglyceridemia, atherosclerosis, and NAFLD.

Other names

Hepatic Very-Low-Density Lipoprotein SynthesisVLDL BiogenesisVLDL Assembly and SecretionLiver VLDL Production

Various, depending on the specific drug. MTP inhibitors directly block VLDL assembly. Insulin sensitizers reduce hepatic glucose production and indirectly affect VLDL synthesis. Lipase inhibitors affect the availability of fatty acids for VLDL synthesis.